Title
Effect of Bacillus Subtilis DE111® on Daily Bowel Movements
The Effect of Bacillus Subtilis DE111® on the Daily Bowel Movement Profile for People With Occasional Gastrointestinal Irregularity
Phase
N/ALead Sponsor
Deerland EnzymesStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Bowel Movement Regulation Occasional Constipation Occasional DiarrheaIntervention/Treatment
Bacillus subtilis DE111®Study Participants
50The purpose of this study is to determine the efficacy of Bacillus subtilis DE111® probiotic for regulation of bowel movements.
The purpose of this study is to determine the efficacy of the probiotic B. subtilis DE111® for regulation of bowel movements. A single capsule containing 1 x 10^9 CFU B. subtilis is to be consumed once a day per participant. 50 adults (18-65 years of age at the time of participation) suffering from occasional constipation and/or diarrhea will be enrolled. Participants will be double-blindly and randomly assigned to either the probiotic (Bacillus subtilis) or the placebo (maltodextrin) group. Efficacy will be assessed with participant-reported bowel movement (BM) records. As a secondary outcome, the study will provide further insight into the tolerance of the supplement. Tolerance will be assessed using a digestive health questionnaire and blood samples to analyze pertinent metabolic biomarkers. Participants will be asked to complete a daily dietary intake record as well. Prior to capsule consumption, participants will complete a two-week pre-testing phase in order to provide a more inclusive diagnostic baseline. This phase will consist of daily BM and dietary intake record keeping.
Subjects were administered a dose of Bacillus subtilis at levels of 1x10^9 CFU once a day for 90-days.
Subjects received a once daily dose of Bacillus subtilis DE111® 1x10^9 CFU for 90-days.
Subjects received a once daily dose of maltodextrin for 90-days.
Inclusion Criteria: Participants suffering from occasional constipation and/or diarrhea will be eligible for participation. Exclusion Criteria: Blood CRP levels for each participant will be monitored at days 0, 60 and 105 of this study. Participants with CRP levels greater than 5mg/l on day 0 of the study will be excluded from further participation as this level is indicative of underlying inflammatory bowel disease. Participants excluded under such conditions will be instructed to seek further treatment with their health care provider.
